Status:
COMPLETED
Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Multicentre Phase II trial, comparing two different administration routes of SLITonePLUS Birch in regard to pharmacodynamic efficacy and tolerability.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A history of Birch pollen allergy
- Positive skin prick test to birch
- Positive specific IgE to birch
- Exclusion criteria:
- Uncontrolled or severe asthma (FEV1\<70% of predicted value in spite of adequate pharmacologic treatment)
- Previous treatment by immunotherapy with birch or a cross-reactingtree pollen allergen within the previous 5 years
- Concomitant SLIT with any allergen
Exclusion
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01191359
Start Date
January 1 2010
End Date
January 1 2011
Last Update
February 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinik Bonn, Dermatology
Bonn, Germany, D-53127